- Supported exchanges /
- F /
- BIX0.F
BIOINVENT INTERN. SK 2 (BIX0 F) stock market data APIs
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.
BIOINVENT INTERN. SK 2 Financial Data Overview
| 3.725 | |
| 3.725 | |
| - | |
| 3.725 | |
| 3.725 | |
| 1.332-4.3 | |
| 249 M | |
| 65 804 K | |
| 38 636 K | |
| 0.38 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
BIOINVENT INTERN. SK 2 Fundamental Data is available in our Financial Data APIs
- Net Revenue 38 636 K
- EBITDA -445 236 000
- Earnings Per Share -0.54
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get BIOINVENT INTERN. SK 2 Earnings via APIs
- Latest Release 2024-10-31
- EPS/Forecast NaN
Get BIOINVENT INTERN. SK 2 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
